Cardiol Therapeutics Class Stock Market Value
| CRDL Stock | USD 1.62 0.04 2.53% |
| Symbol | Cardiol |
Cardiol Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cardiol Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cardiol Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cardiol Therapeutics.
| 06/08/2023 |
| 11/29/2024 |
If you would invest 0.00 in Cardiol Therapeutics on June 8, 2023 and sell it all today you would earn a total of 0.00 from holding Cardiol Therapeutics Class or generate 0.0% return on investment in Cardiol Therapeutics over 540 days. Cardiol Therapeutics is related to or competes with Haleon Plc, and Intracellular. Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibro... More
Cardiol Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cardiol Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cardiol Therapeutics Class upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 19.95 | |||
| Value At Risk | (5.73) | |||
| Potential Upside | 5.62 |
Cardiol Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiol Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cardiol Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cardiol Therapeutics historical prices to predict the future Cardiol Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.81) | |||
| Treynor Ratio | (0.37) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiol Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiol Therapeutics Backtested Returns
Cardiol Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0584, which signifies that the company had a -0.0584% return per unit of risk over the last 3 months. Cardiol Therapeutics Class exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cardiol Therapeutics' Standard Deviation of 3.75, risk adjusted performance of (0.04), and Mean Deviation of 2.91 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cardiol Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cardiol Therapeutics is expected to be smaller as well. At this point, Cardiol Therapeutics has a negative expected return of -0.22%. Please make sure to confirm Cardiol Therapeutics' potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Cardiol Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.18 |
Insignificant reverse predictability
Cardiol Therapeutics Class has insignificant reverse predictability. Overlapping area represents the amount of predictability between Cardiol Therapeutics time series from 8th of June 2023 to 4th of March 2024 and 4th of March 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cardiol Therapeutics price movement. The serial correlation of -0.18 indicates that over 18.0% of current Cardiol Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.18 | |
| Spearman Rank Test | -0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Cardiol Therapeutics lagged returns against current returns
Autocorrelation, which is Cardiol Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cardiol Therapeutics' stock expected returns. We can calculate the autocorrelation of Cardiol Therapeutics returns to help us make a trade decision. For example, suppose you find that Cardiol Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cardiol Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cardiol Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cardiol Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cardiol Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Cardiol Therapeutics Lagged Returns
When evaluating Cardiol Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cardiol Therapeutics stock have on its future price. Cardiol Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cardiol Therapeutics autocorrelation shows the relationship between Cardiol Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Cardiol Therapeutics Class.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Cardiol Therapeutics Correlation, Cardiol Therapeutics Volatility and Cardiol Therapeutics Alpha and Beta module to complement your research on Cardiol Therapeutics. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Cardiol Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.